Bone Loss

Truvada PrEP Causes Only Minimal Bone Loss, Raltegravir Easier on Bones than PIs2

Use of tenofovir/emtricitabine (Truvada) for HIV pre-exposure prophylaxis (PrEP) was associated with a small decrease in bone mineral density that stabilized after the first 6 months, according to study findings reported in the April 23 edition of Clinical Infectious Diseases. Related research showed that HIV-positive people starting an antiretroviral regimen containing the integrase inhibitor raltegravir (Isentress) experienced less bone loss than those taking protease inhibitors.

alt

Read more:

CROI 2015: FRAX Fracture Prediction Tool Underestimates Fracture Risk in Men with HIV

The Fracture Risk Assessment Tool (FRAX), an online tool developed by the World Health Organization and used to help guide decisions about who to screen or treat in order to prevent bone fractures, underestimates overall risk of fracture in people living with HIV -- even with an adjustment experts have recommended to improve its accuracy for people with HIV -- according to an analysis of the Veterans Aging Cohort Study Virtual Cohort (VACS-VC) reported at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

Read more:

People with HIV Have Higher Bone Fracture Risk in Danish Study

Being HIV positive was associated with a nearly 3-fold greater likelihood of bone fractures overall -- and a 9-fold higher risk of hip and spine fractures -- compared with HIV negative people, according to results from a large Danish population study described in the May 1 Journal of Acquired Immune Deficiency Syndromes.

alt

Read more:

Screening for Bone Fracture Risk Should Be Routine for HIV+ People over 40

Screening for fracture risk should be a routine part of HIV care for all people over 40, and all postmenopausal women, all men over 50, and people at high risk for fractures of any age should undergo DEXA screening (a type of X-ray) to assess bone mineral density and their need for treatment, experts on bone disorders recommend in new guidelines published in the January 21 online edition of Clinical Infectious Diseases.

alt

Read more:

CROI 2014: Vitamin D and Rosuvastatin Improve Bone Loss in People with HIV

A combination of high-dose vitamin D and calcium may help reduce bone loss after starting antiretroviral therapy (ART), according to a presentation at the Conference on Retroviruses and Opportunistic Infections (CROI 2014) last month in Boston. A related study found that rosuvastatin increased hip bone mineral density in HIV positive people on ART, though insulin resistance worsened.

alt

Read more: